


ORDERING INFORMATION FOR SHINGRIX



SHINGRIX 1-dose pack NDC 58160-819-12

Case Dimensions	13.46" x 16.96" x 9.88"
Unit Dimensions	5.23" x 1.65" x 0.94"
Adjuvant Suspension Component (Vial 1 of 2)	NDC 58160-829-01
Lyophilized gE Antigen Component (Vial 2 of 2)	NDC 58160-828-01
gE=glycoprotein E.	

SHINGRIX 10-dose pack NDC 58160-823-11

Case Dimensions	16.30" x 9.37" x 12.76"
Unit Dimensions	3.54" x 2.95" x 1.65"
Adjuvant Suspension Component (10 vials)	NDC 58160-829-03
Lyophilized gE Antigen Component (10 vials)	NDC 58160-828-03
gE=glycoprotein E.	

DO NOT FREEZE SHINGRIX

STORAGE, RECONSTITUTION, AND ADMINISTRATION

- SHINGRIX should be refrigerated, not frozen. Store both the antigen and adjuvant between 2° and 8°C (36° and 46°F) before reconstitution (discard if frozen). Protect vials from light
- SHINGRIX is supplied as an adjuvant and antigen for reconstitution. The antigen is to be reconstituted only with the accompanying adjuvant suspension. After reconstitution, SHINGRIX should be administered immediately or stored refrigerated between 2° and 8°C (36° and 46°F) and used within 6 hours. Discard reconstituted vaccine if not used within 6 hours or if frozen
- SHINGRIX is administered intramuscularly as a 2-dose series. The second dose can be administered anytime between 2 and 6 months after the first dose



Please see Indication and Important Safety Information for SHINGRIX on back. Please see accompanying full Prescribing Information for SHINGRIX.

BILLING, CODING, AND INSURANCE

CPT Code (Product)	90750
CPT Code (Administration) 1 vaccine administered Each additional vaccine administered during same encounter	90471 90472
ICD-10-CM Code (Encounter for Immunization)	Z23
Administration Modifier for Medicare	GY
MVX Code	SKB
CVX Code	187

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

IMPORTANT SAFETY INFORMATION

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
- Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
- SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see accompanying full Prescribing Information for SHINGRIX.

**FOR QUESTIONS REGARDING SHINGRIX, CALL 1-800-772-9292
OR CONTACT YOUR GSK REPRESENTATIVE.**



All trademarks are the property of their respective owners.



©2018 GSK group of companies or its licensor.
Printed in USA. 830715R0 January 2018